Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 25, 2025, titled "Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg".
Press Release Nov 25 2025
Filed with NSE · · 2 pages · English
Release
Zydus Lifesciences Limited on 6ix
In the deck
Earlier from Zydus Lifesciences
- Press Release Nov 14 2025
- Press Release Nov 13 2025
- Press Release Nov 11 2025
- Press Release Nov 07 2025
- Press Release Nov 06 2025
Later from Zydus Lifesciences
- Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market
- Press Release Nov 26 2025
- Press Release Nov 27 2025
- Press Release Dec 04 2025
- Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences